Benralizumab

證據等級: L5

預測適應症: 5 個

Benralizumab: From Severe Eosinophilic Asthma to Dermatitis

One-Sentence Summary

Benralizumab is an anti-IL-5 receptor α (IL-5Rα) monoclonal antibody proven effective in severe eosinophilic asthma, acting by depleting eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity (ADCC). The TxGNN model predicts it may be effective for Dermatitis, with 6 clinical trials and 20 publications currently supporting this direction. However, the pivotal Phase 2 RCT (HILLIER, NCT04605094, n=194) was terminated early with negative results for broad atopic dermatitis, suggesting any remaining opportunity is restricted to eosinophil-predominant subtypes such as DRESS/DiHS.

Quick Overview

Item	Content
Original Indication	Severe eosinophilic asthma (globally approved; not found in current dataset)
Predicted New Indication	Dermatitis
TxGNN Prediction Score	99.16%
Evidence Level	L2
US Market Status	Not Marketed (0 records in current registry)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Benralizumab binds directly to IL-5Rα on eosinophils and basophils, triggering ADCC-mediated near-complete depletion of these cells. This mechanism was validated in severe eosinophilic asthma, where excessive eosinophil-driven airway inflammation drives disease. Because IL-5Rα is expressed broadly wherever eosinophils accumulate — not just in the lung — the biological rationale for extending benralizumab to other eosinophilic conditions is sound in principle.

Dermatitis, particularly atopic dermatitis (AD) and drug reaction with eosinophilia and systemic symptoms (DRESS/DiHS), shares key pathophysiological features with eosinophilic asthma: tissue eosinophilia, type 2 innate lymphoid cell (ILC2) activation, and IL-5 overproduction driving eosinophil recruitment and prolonged survival in affected tissue. A 2025 translational study (PMID 40781582) directly confirmed that benralizumab depletes IL-5Rα-bearing cells in AD skin lesions, establishing that the drug does reach and engage its target at the disease site.

Despite this biologically coherent hypothesis, the HILLIER trial (NCT04605094) — a randomized, double-blind, placebo-controlled study enrolling 194 patients with moderate-to-severe AD — was terminated early due to lack of efficacy (PMID 37178404). This outcome highlights that for most AD patients, where the dominant inflammatory drivers are IL-4 and IL-13 rather than IL-5, depleting eosinophils alone is insufficient. The remaining mechanistically justified niche lies in diseases where eosinophilia is a defining — not incidental — feature: DRESS/DiHS is the clearest candidate, and an active Phase 2 trial (NCT06734884) is currently addressing this question.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06734884	Phase 2	Not Yet Recruiting	96	Evaluating benralizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) — eosinophils are a defining feature of DRESS pathology, making IL-5Rα depletion mechanistically compelling; highest-priority active study for this indication
NCT03563066	Phase 2	Completed	20	Exploratory study of benralizumab in atopic dermatitis — confirmed eosinophil and basophil depletion in skin (target engagement proven), but limited clinical response; small sample size; provides critical biomarker data for patient selection in future trials
NCT04605094	Phase 2	Terminated	194	HILLIER Study — randomized, double-blind, placebo-controlled RCT in moderate-to-severe AD; terminated early due to lack of efficacy; combined with PMID 37178404, this constitutes the principal negative evidence against broad AD indication
NCT06477653	Phase 2	Recruiting	30	Dupilumab add-on therapy in hypereosinophilic syndrome (HES) patients with partial response to eosinophil-depleting biologics — indirect evidence relevant to eosinophilic skin overlap; supports the residual-eosinophil hypothesis in refractory cases
NCT04126499	N/A	Completed	28	Observational retrospective study of benralizumab in severe eosinophilic asthma in Spain — real-world safety profile and responder phenotype characterization; provides supporting safety context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37178404	2023	Phase 2 RCT	JEADV	KEY NEGATIVE: HILLIER primary results — benralizumab showed no significant effect on signs or symptoms of moderate-to-severe AD; critical evidence against pursuing broad atopic dermatitis indication
38695680	2024	Phase 2 RCT	Immunotherapy	HILLIER plain language summary — confirms early termination and negative outcome; underscores the need for eosinophil-enriched patient selection in any future dermatitis trials
40781582	2025	Mechanistic Study	Clin Transl Allergy	Benralizumab depletes IL-5Rα-bearing cells in AD skin lesions — validates target engagement in skin tissue; distinguishes pharmacological activity from clinical efficacy
39600395	2024	Narrative Review	Allergologie select	Comprehensive update on biologics for atopic diseases and urticaria including benralizumab; positions anti-IL-5Rα within the evolving type 2 biologics landscape
36355314	2023	Review	Dermatology and Therapy	Dupilumab combination strategies — contextualizes scenarios where add-on benralizumab may be considered for AD patients with concomitant eosinophilic conditions
36411004	2023	Review	Immunol Allergy Clin N Am	Biologics (including benralizumab) during pregnancy and lactation — key reference for safety profiling in women of childbearing age presenting with dermatitis
35987486	2022	Review	J Allergy Clin Immunol Pract	Safety review of 7 FDA-approved biologics including benralizumab during pregnancy — summarizes maternal and fetal outcomes relevant to special population counselling
33236428	2020	Review	Pediatr Allergy Immunol	Anti-IL-5 biologics in pediatric allergic diseases — background on the IL-5 axis in childhood atopic dermatitis and rationale for eosinophil-targeting approaches
34642091	2021	Review	Ann Allergy Asthma Immunol	Practical guide for biologic selection across asthma, urticaria, nasal polyps, and atopic dermatitis — includes benralizumab positioning and emerging indications
31690400	2019	Narrative Review	Allergy Asthma Proc	Review of anti-IL-5 biologics (mepolizumab, reslizumab, benralizumab) for severe asthma, atopic dermatitis, and chronic urticaria — foundational reference for the eosinophil-dermatitis hypothesis

US Market Information

No authorization records were found in the current regulatory dataset (0 NDAs on file). The registry query returned no approved indications for benralizumab in this dataset.

Note: Benralizumab is marketed globally as Fasenra (AstraZeneca) and is FDA-approved in the United States for severe eosinophilic asthma. The absence of records above likely reflects a data gap in the current registry rather than actual non-approval status. Please verify against the official FDA Drugs@FDA database for US authorization details.

Safety Considerations

Please refer to the package insert for safety information.

No warnings, contraindications, or drug interaction data were available in the current dataset. As a biologic monoclonal antibody, benralizumab carries class-level considerations including hypersensitivity reactions and potential effects on vaccine responses (see PMID 38878020 for reduced post-vaccination SARS-CoV-2 immunity observed with benralizumab and related biologics).

Conclusion and Next Steps

Decision: Hold

Rationale: The highest-quality direct evidence — the HILLIER Phase 2 RCT (NCT04605094, n=194) — demonstrated no efficacy for benralizumab in broad moderate-to-severe atopic dermatitis and was terminated early, making a general “dermatitis” indication untenable under current evidence. The mechanistic rationale remains valid only for eosinophil-predominant disease subtypes, principally DRESS/DiHS, which is still under active investigation.

To proceed, the following is needed:

Await DRESS trial results: NCT06734884 (Phase 2, n=96) is the pivotal next data point; monitor for recruitment initiation and interim data
Biomarker-driven patient selection: Define minimum blood/tissue eosinophil thresholds (e.g., blood eosinophils ≥300 cells/μL, tissue eosinophil density in biopsy) as enrollment criteria for any new dermatitis study
Safety data: Obtain full package insert warnings and contraindications to enable regulatory-compliant benefit-risk assessment
Mechanistic gap fill: Clarify why target engagement (PMID 40781582) did not translate to clinical response in HILLIER — explore whether IL-4/IL-13 pathway compensates in broad AD
MOA documentation: Retrieve complete DrugBank pharmacology record (DrugBank ID: DB12023) to support regulatory submissions and clinician communications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.